DK468880A - Fremgangsmaade til fremstilling af enzymderivater - Google Patents

Fremgangsmaade til fremstilling af enzymderivater

Info

Publication number
DK468880A
DK468880A DK468880A DK468880A DK468880A DK 468880 A DK468880 A DK 468880A DK 468880 A DK468880 A DK 468880A DK 468880 A DK468880 A DK 468880A DK 468880 A DK468880 A DK 468880A
Authority
DK
Denmark
Prior art keywords
procedure
preparing enzyme
enzyme derivatives
derivatives
preparing
Prior art date
Application number
DK468880A
Other languages
English (en)
Other versions
DK158994C (da
DK158994B (da
Inventor
R A G Smith
J G Winchester
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of DK468880A publication Critical patent/DK468880A/da
Publication of DK158994B publication Critical patent/DK158994B/da
Application granted granted Critical
Publication of DK158994C publication Critical patent/DK158994C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK468880A 1979-11-05 1980-11-04 Analogifremgangsmaade til fremstilling af enzymderivater indeholdende et streptokinase/plasminogen-kompleks DK158994C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7938279 1979-11-05
GB7938279 1979-11-05

Publications (3)

Publication Number Publication Date
DK468880A true DK468880A (da) 1981-05-06
DK158994B DK158994B (da) 1990-08-13
DK158994C DK158994C (da) 1991-01-07

Family

ID=10508982

Family Applications (1)

Application Number Title Priority Date Filing Date
DK468880A DK158994C (da) 1979-11-05 1980-11-04 Analogifremgangsmaade til fremstilling af enzymderivater indeholdende et streptokinase/plasminogen-kompleks

Country Status (18)

Country Link
US (1) US4808405A (da)
EP (1) EP0028489B1 (da)
JP (1) JPS5678590A (da)
AR (1) AR224786A1 (da)
CA (1) CA1174621A (da)
CS (2) CS391991A3 (da)
DE (1) DE3065190D1 (da)
DK (1) DK158994C (da)
ES (1) ES8204467A1 (da)
GR (1) GR72121B (da)
HK (1) HK65886A (da)
HU (1) HU185223B (da)
IE (1) IE50174B1 (da)
IL (1) IL61408A (da)
NL (1) NL930029I2 (da)
NO (1) NO163867C (da)
NZ (1) NZ195469A (da)
ZA (1) ZA806641B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3361610D1 (en) * 1982-04-07 1986-02-06 Beecham Group Plc Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
EP0125269A1 (en) * 1982-11-11 1984-11-21 Beecham Group Plc Pharmaceutically active compounds
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5231006A (en) * 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
JPH0296536A (ja) * 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
AU647391B2 (en) * 1989-05-01 1994-03-24 University Of Notre Dame Du Lac, The Methods and materials for expression of human plasminogen in a eukaryotic cell system
EP0397366A1 (en) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
ATE135200T1 (de) * 1989-05-17 1996-03-15 Res Corp Technologies Inc Verfahren und zusammensetzung zur thrombosebehandlung beim säugetier
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
GB8928163D0 (en) * 1989-12-13 1990-02-14 Beecham Group Plc Novel treatment
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5187069A (en) * 1990-08-06 1993-02-16 Henry Ford Health System Active site labelling of plasminogen
AU1873092A (en) * 1991-04-09 1992-11-17 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
ES2239806T3 (es) 1997-06-19 2005-10-01 Bristol-Myers Squibb Pharma Company Inhibidores del factor xa con un grupo de especificidad neutro p1.
TWI290146B (en) * 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
KR20010000669A (ko) * 2000-10-12 2001-01-05 김기환 스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
CA2726702A1 (en) 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｘｉａ因子阻害剤としての置換ビアリール化合物
DE602006020327D1 (de) 2005-01-19 2011-04-07 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006017694D1 (de) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
KR20080027890A (ko) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제
EP2061756B1 (en) 2006-06-08 2013-09-25 Bristol-Myers Squibb Company 2-aminocarbonylphenylamino-2-phenilacetamides as factor viia inhibitors useful as anticoagulants
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
US8367709B2 (en) 2007-06-13 2013-02-05 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
PE20091972A1 (es) 2008-05-19 2010-01-15 Schering Corp Compuestos heterociclicos como inhibidores del factor ixa
EP3520776A1 (en) 2009-06-16 2019-08-07 Pfizer Inc Dosage forms of apixaban
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
SG183153A1 (en) 2010-02-11 2012-09-27 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
MY165742A (en) 2011-10-14 2018-04-23 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
UA108713C2 (xx) 2011-11-11 2015-05-25 2-тіопіримідинони
CN104334557A (zh) 2012-04-06 2015-02-04 辉瑞公司 二酰基甘油酰基转移酶2抑制剂
TW201410667A (zh) 2012-08-03 2014-03-16 必治妥美雅史谷比公司 二氫吡啶酮ｐ１作爲凝血因子ｘｉａ抑制劑
WO2014022766A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
CA2926568C (en) 2013-10-09 2017-09-05 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
EP3988549A1 (en) 2014-01-31 2022-04-27 Bristol-Myers Squibb Company Macrocycles with heterocyclic p2' groups as factor xia inhibitors
NO2760821T3 (da) 2014-01-31 2018-03-10
CR20160405A (es) 2014-03-17 2016-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
EP3126330B1 (en) 2014-04-04 2019-02-27 Pfizer Inc Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EP3131897B8 (en) 2014-04-16 2022-08-03 Merck Sharp & Dohme LLC Factor ixa inhibitors
NO2721243T3 (da) 2014-10-01 2018-10-20
EP3292109A1 (en) 2015-05-05 2018-03-14 Pfizer Inc 2-thiopyrimidinones
SG10201912333PA (en) 2015-06-17 2020-02-27 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
CN107922393A (zh) 2015-07-29 2018-04-17 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
LT3341367T (lt) 2015-08-27 2021-04-26 Pfizer Inc. Biciklinis sulietas heteroarilas arba arilo junginiai kaip irak4 moduliatoriai
WO2017151746A1 (en) 2016-03-02 2017-09-08 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
US20220387402A1 (en) 2019-05-20 2022-12-08 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
EP4185587A1 (en) 2020-07-22 2023-05-31 JANSSEN Pharmaceutica NV Compounds useful as factor xia inhibitors
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178368A (en) * 1971-09-30 1979-12-11 Behringwerke Aktiengesellschaft Method for the treatment of thromboembolism
JPS5325775A (en) * 1976-08-24 1978-03-09 Miller Fluid Power Corp Module type fluid flow control element
US4082612A (en) * 1976-09-24 1978-04-04 Michael Reese Research Foundation Plasminogen activator complex
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions

Also Published As

Publication number Publication date
ES496586A0 (es) 1982-05-01
DE3065190D1 (en) 1983-11-10
NO163867B (no) 1990-04-23
JPS5678590A (en) 1981-06-27
NL930029I1 (nl) 1993-06-01
ES8204467A1 (es) 1982-05-01
IE50174B1 (en) 1986-02-19
DK158994C (da) 1991-01-07
GR72121B (da) 1983-09-16
IL61408A0 (en) 1980-12-31
EP0028489B1 (en) 1983-10-05
NO163867C (no) 1990-08-01
US4808405A (en) 1989-02-28
IE802277L (en) 1981-05-05
HK65886A (en) 1986-09-12
EP0028489A1 (en) 1981-05-13
HU185223B (en) 1984-12-28
ZA806641B (en) 1981-10-28
CS391991A3 (en) 1992-06-17
AR224786A1 (es) 1982-01-15
NZ195469A (en) 1984-05-31
DK158994B (da) 1990-08-13
CS391191A3 (en) 1992-08-12
AU6401180A (en) 1981-05-14
JPH0316114B2 (da) 1991-03-04
NL930029I2 (nl) 1993-12-01
AU534017B2 (en) 1983-12-22
CA1174621A (en) 1984-09-18
NO803304L (no) 1981-05-06
IL61408A (en) 1983-10-31

Similar Documents

Publication Publication Date Title
DK468880A (da) Fremgangsmaade til fremstilling af enzymderivater
DK540080A (da) Fremgangsmaade til fremstilling af 2-amino-4-hydroxyquinazolinderivater
DK363179A (da) Fremgangsmaade til fremstilling af tetrazolylalkoxycarbostyrilderivater
DK457779A (da) Fremgangsmaade til fremstilling af 4-hydroxy-2-pyronderivater
DK147225C (da) Fremgangsmaade til fremstilling af intravenoest indgivelige immunogammaglobulinderivater
DK365280A (da) Fremgangsmaade til fremstilling af ftaliminderivater
DK488379A (da) Fremgangsmaade til fremstilling af polyetherderivater
DK294880A (da) Fremgangsmaade til fremstilling af n-phosphonomethylglycin
DK394080A (da) Fremgangsmaade til fremstilling af carbostyrilderivater
DK413780A (da) Fremgangsmaade til fremstilling af d-6-n-propylergoliner
DK54280A (da) Fremgangsmaade til fremstilling af heterotricykliske derivater
DK316480A (da) Fremgangsmaade til fremstilling af pyridazinderivater
DK396880A (da) Fremgangsmaade til fremstilling af cyclohexancarboxylsyrederivater
DK138879A (da) Fremgangsmaade til fremstilling af lysergolderivater
DK187980A (da) Fremgangsmaade til fremstilling af benzimidazolderivater
DK205580A (da) Fremgangsmaade til fremstilling af benzodiazepinderivater
DK222880A (da) Fremgangsmaade til fremstilling af anthracyclinonderivater
DK304080A (da) Fremgangsmaade til fremstilling af pyrazoloindazolderivater
DK177680A (da) Fremgangsmaade til fremstilling af 7-n-heterocyclyl-cephalosporiner
DK395880A (da) Fremgangsmaade til fremstilling af pyridazinderivater
DK134880A (da) Fremgangsmaade til fremstilling af benzothiazolderivater fremgangsmaade til fe
DK157850C (da) Fremgangsmaade til fremstilling af 7-acylindolin-2-oner
DK183780A (da) Femgangsmaade til fremstilling af hydroxyderivater af isopropylaminopyrimidin
DK342079A (da) Fremgangsmaade til fremstilling af carbostyrilderivater
DK12879A (da) R fremgangsmaade til fremstilling af ergopeptidalkaloidderivate

Legal Events

Date Code Title Description
PBP Patent lapsed